The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Real-world outcomes of varnimcabtagene autoleucel in B-cell lymphoma and toxicity challenges
Rohan Halder, MBBS, MD, DM, PDCC, Rajiv Gandhi Cancer Institute, Delhi, India, discusses the real-world safety and efficacy of varnimcabtagene autoleucel, a murine CD19 CAR-T therapy, in patients with B-cell non-Hodgkin lymphoma (NHL). Results demonstrated that most patients achieved complete remission (CR) and measurable residual disease (MRD) negativity after one or two cycles. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
